EU/3/03/144: Orphan designation for the treatment of congenital ichthyoses


Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in July 2015 on request of the Sponsor.

On 10 June 2003, orphan designation (EU/3/03/144) was granted by the European Commission to Barrier Therapeutics NV, Belgium, for liarozole for the treatment of congenital ichthyoses.

The sponsorship was transferred to Stiefel Laboratories (U.K.) Limited, United Kingdom, in June 2010.

Key facts

Active substance
Intended use
Treatment of congenital ichthyoses
Orphan designation status
EU designation number
Date of designation
Stiefel Laboratories (U.K.) Limited
Eurasia Headquarters
Concorde Road
Maidenhead SL6 4BY
United Kingdom
Telephone: +44 1628 612 260
Telefax: +44 1628 612 000

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating